Mod­er­na dou­bles down on rare dis­eases; FDA ad­vi­so­ry com­mit­tee votes on fall Covid cam­paign; Il­lu­mi­na CEO steps down; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As a re­minder, the End­points team will be off on Mon­day. We’ll be back in your in­box on Tues­day, and keep an eye out for our vir­tu­al cov­er­age of the 2023 Cannes Li­ons In­ter­na­tion­al Fes­ti­val of Cre­ativ­i­ty. Phar­ma ad­ver­tis­ing award sub­mis­sions surged al­most 20% this year, and we’ll tell you all you need to know about this year’s win­ners. — Nicole De­Feud­is

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER